Published by Josh White on 29th January 2026
(Sharecast News) - Roche reported a solid rise in earnings in 2025 on Thursday, but struck a cautious note on the outlook, as currency headwinds and softer-than-expected sales of a key eye drug tempered an otherwise improving performance driven by newer medicines and recent clinical successes.